Browse the evidence

The proposed nanocomplex is a promising system for long-acting injectable delivery of semaglutide, potentially enhancing patient compliance.

This delivery system may improve treatment adherence in patients requiring semaglutide.

GLP-1 RA initiation was associated with a reduced incidence rate of alcohol use disorders (AUD) post RYGB (1.1% vs. 1.8%) with a hazard ratio of 0.77.

Practitioners may consider GLP-1 RAs as a strategy to reduce AUD in patients post RYGB.

GLP-1 receptor agonists (GLP-1 RAs) can lead to modest yet statistically significant reductions in systolic blood pressure (SBP).

GLP-1 RAs may be considered as adjunctive therapies for managing hypertension.

Recent innovations in bariatric research include pharmacological therapies targeting GLP-1 receptors, minimally invasive procedures, and genetic and microbiome-based strategies.

These innovations may provide new options for obesity treatment.

Intensive glycemic control can precipitate hypoglycemic events, which may lead to serious complications.

Healthcare providers should monitor patients closely to prevent hypoglycemic events during intensive glycemic control.

Recommendations for collaborative action include developing obesity education and care standards that incorporate patients' perspectives.

Healthcare systems should prioritize patient-centered approaches in obesity care.

Metabolic disorders such as obesity, type 2 diabetes, and dyslipidaemia are major drivers of cardiovascular risk.

Practitioners should focus on addressing metabolic disorders to reduce cardiovascular risk.

Emerging therapies for genetic and syndromic obesities include approved treatments like setmelanotide and semaglutide.

Practitioners should consider the use of approved therapies like setmelanotide and semaglutide in treatment plans.

New pharmacological approaches aim to conserve lean body mass during weight loss.

Emerging drugs may help maintain muscle mass during weight loss, which is crucial for long-term success.

GLP-1 receptor agonists are approved for steatotic liver disease, with demonstrated histologic and biochemical benefits.

GLP-1 receptor agonists can be utilized in clinical practice for managing steatotic liver disease effectively.

The evolution of anti-obesity pharmacotherapy has progressed to modern gut hormone-based therapies, notably glucagon-like peptide-1 receptor agonists (GLP-1RAs), which effectively suppress appetite and improve glycemic control.

Practitioners should consider GLP-1RAs as effective options for appetite control and glycemic management in obesity treatment.

Among 11,700 reports from July 2009 to April 2024, 13 incidents related to GLP-1 agonist use were identified, including seven cases concerning aspiration.

Clinicians should be aware of the potential aspiration risks associated with GLP-1 agonist use in the perioperative setting.

Exenatide combined with Metformin improved 2-hour oral glucose tolerance test (OGTT) values by a mean difference of -1.78 (p < 0.001).

The combination therapy may enhance glucose tolerance in women with PCOS.

HbA1c decreased from 5.5 ± 0.3 at baseline to 5.3 ± 0.3 at 12 weeks and to 5.2 ± 0.027 at 24 weeks.

Practitioners can expect improvements in glycemic control in patients using compounded GLP-1 ± GIP agonists.

Multiple incretin pharmaceutical agents show promise in the prevention and treatment of T2D.

Stay informed about new incretin agents for T2D prevention and treatment.

Ingestion of a single bolus of hydrolyzed collagen or free amino acids substantially increases circulating amino acids concentrations, particularly glycine.

Practitioners can consider collagen and amino acid supplementation to enhance amino acid availability post-exercise.

MRs significantly reduce glycated hemoglobin (HbA1c) levels by 0.24%.

Using meal replacements can lead to better long-term glucose management.

MRs cause a greater decrease in FBS, insulin, and HOMA-IR in individuals over 50 years old compared to those aged 50 years or younger.

Older adults may benefit more from meal replacements in terms of glucose metabolism.

The primary outcome of the RESTART trial is a change in cardiorespiratory fitness (V̇O 2max) at 24 months.

Monitoring changes in cardiorespiratory fitness can be crucial for assessing the effectiveness of lifestyle interventions.

Weight increases of 1.0% to 2.9%, 3.0% to 4.9%, and 5.0% or greater are associated with a higher risk of type 2 diabetes by 15%, 35%, and 51%, respectively.

Weight gain should be avoided to reduce the risk of developing type 2 diabetes.

Acute data generally show that muscle activation and training volume do not differ between supersets and traditional resistance training.

Both training methods can be considered equally effective in terms of muscle activation and volume.

Plasma essential amino acid concentrations increased after protein ingestion, but did not differ between recombinant bovine β-lactoglobulin (rBLG) and whey.

Both rBLG and whey can effectively increase amino acid levels post-ingestion, making them viable protein sources.

Faster resistance training tempos may have a trivial advantage over slower tempos for muscle hypertrophy.

Practitioners might consider that while faster tempos could be slightly more beneficial, the difference is not significant.

Subgroup analyses indicate trivial to small effects of resistance training tempo on muscle hypertrophy under specific conditions.

Practitioners should be aware that the effects of tempo may vary based on specific training conditions.